retatrutide phase 2 nejm 2023 obesity trial results For patients with #obesity, semaglutide, a glucagon-like peptide-1 receptor agonist, is approved for weight management as a once-weekly subcutaneous injection. In a previous trial, oral semaglutide at a dose of 50 mg Weight Regain after Stopping Obesity

Wait at least 30 min before the first meal or drink of the day or taking other oral medicinal products

[2] Dulaglutide (Trulicity), another once-weekly injectable GLP-1 agonist, demonstrates a somewhat more favourable gastrointestinal tolerability profile in some studies, with nausea reported in approximately 8-12% of patients at lower doses, though rates increase with higher doses (3

A nationwide cohort study from Sweden and Denmark found no significant increase in suicide deaths among GLP-1 RA users compared to Sodium-glucose cotransporter-2 (SGLT2) inhibitors, and even reported a lower incidence of combined suicide and self-harm outcomes (HR 0.83) [47]

States continue to consider PBM reform